Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 80,000,000
Countries
Sector(s)
Italy : € 80,000,000
Industry : € 80,000,000
Signature date(s)
8/09/2014 : € 30,000,000
30/07/2014 : € 50,000,000
Link to source

Summary sheet

Release date
1 October 2013
Status
Reference
Signed | 30/07/2014
20130282
Project name
Promoter - financial intermediary
CHIESI RESPIRATORY R&D
CHIESI FARMACEUTICI SPA
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 80 million
EUR 184 million
Location
Sector(s)
Description
Objectives

Financing Chiesi Farmaceutici's late stage clinical R&D programme and regulatory approval for the period 2014-2015 for (i) the development of new treatments for respiratory diseases with a particular focus on Asthma and Chronic Obstructive Pulmonary Disease (COPD) and (ii) Infant Respiratory Distress Syndrome (IRDS).

The project aims at strengthening the promoter’s research efforts in the selected therapeutic areas, mainly asthma and COPD. The project will be mostly carried out in the promoter’s R&D centre in Parma (Italy).

Environmental aspects
Procurement

The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorized for the same purpose and would therefore not require an EIA under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter’s procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project due diligence.

Link to source
Other links

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Documents

Environmental and Social Data Sheet (ESDS) - CHIESI RESPIRATORY R&D
Publication Date
14 Feb 2014
Document language
Main Topic
Lending
Document Number
48714491
Document Focus
Environmental Information
Project Number
20130282
Sector(s)
Regions
Countries
Publicly available
Download now
Environmental and Social Completion Sheet (ESCS) - CHIESI RESPIRATORY R&D
Publication Date
9 Oct 2017
Document language
Main Topic
Lending
Document Number
67643523
Document Focus
Environmental Information
Project Number
20130282
Sector(s)
Regions
Countries
Publicly available
Download now
Other links

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications